March 30, 2015

Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma

Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval allows for rapid, direct commercial market access in Japan, the world’s second largest medical device market Optune™ (formerly NovoTTF™-100A System) (Photo: Business Wire) March 30, 2015 08:00 AM… Read More
learn more